June 13, 2016 — Teva Pharmaceuticals has recalled the Zecuity migraine patch after the FDA received a large number of reports involving severe burns and permanent scarring.
The FDA issued a warning about Zecuity on June 2. On June 10, Teva sent a “Dear Doctor” letter (PDF) asking healthcare professionals to stop prescribing Zecuity and switch patients to another headache medicine.
The company will voluntarily suspend all sales, marketing, and distribution while they investigate Zecuity injury reports.
In many reports, symptoms improved in a few hours or weeks. However, there are reports of patients experiencing long-term skin problems — primarily skin discoloration — lasting several months. According to Teva:
“Descriptions of these reactions have included severe redness, cracked skin, blistering or welts, and burns or scars where the patch was worn. Patients described severe pain, itching, or burning.”
Zecuity is a single-use, battery-powered patch that uses a tiny electrical current to deliver the active drug sumatriptan through the skin. Sumatriptan is sold as a pill under the brand Imitrex.
Zecuity has been on the market since September 2015. In clinical trials, about one-quarter of patients complained about pain, and more than half of patients experienced persistent redness. The most common side effects are pain, tingling, itching, warmth, discomfort, and skin discoloration.
Do I have a Zecuity Lawsuit?
The Schmidt Firm, PLLC is currently accepting Zecuity induced injury cases in all 50 states. If you or somebody you know has been developed severe burns or scars, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Medical Device Litigation Group or call toll free 24 hours a day at (866) 920-0753.
Attention Lawyers: We consider a referral from another law firm to be one of the greatest compliments. If your firm is interested in referring us a case or for us to send you a list of previous award judgments and/or average referral fees, please visit the Lawyer Referral section of our website.